Redeye comments on Tessin’s Q4 results, which were softer than expected.
Redeye reinforces its positive view on Transtema following a Q4 report showing strong development in...
Sales +36% and EBIT +82% vs. ABGSCe Expect cons. to raise '25e-'26e sales by ~15% Overall a strong b...
Fiskars Q4 adjusted EBIT of EUR 42.9m came 2% above Modular Finance consensus expectations.
Sales SEK 630m, -15% vs. ABGSCe EBIT of SEK 51m, -5% vs.
Binero Group acquires 100% of IT Partner i Tromsø AS (Serit Tromsø).
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a...
Redeye’s first take on the Q4 report this morning. Again, there were considerable changes in sales i...
Redeye is encouraged to see organic growth in the quarter after a relatively weak performance during...
Redeye provides an in-depth review of Episurf Medical’s Q4 report and events during and after the qu...
Redeye initiates coverage of NextCell Pharma, a clinical-stage biotech company developing a cell the...
Redeye updates its estimates and valuation following Vitec releasing its Q4 2024 report.
Q4'24 results due 11 February '25e-'26e adj. EBIT revised by 0.
Q4 report on Thursday, 13 February Centennial Flats the largest Q4 contributor Expecting updates on ...
NOI +41% y-o-y and +1% vs ABGSCe Value uplift -0.3% q-o-q, net LTV at 52.
Finnair reports Q4 results on Feb 13. Q4 traffic data was mostly encouraging even if European routes...
F&MT initiates cost-cutting program Gradual recovery expected Q4 due on 10 February Q4e: Organic sa...
We maintain our estimates intact ahead of CapMan’s Q4 report, due on 13 February.
Redeye shares its initial thoughts on CTEK’s Q4 report.
Redeye’s first comments follow this morning’s Q4 report from Tagmaster.
